TARGETING OF LYSYL OXIDASE-LIKE-2 (LOXL2) PROMOTES REVERSAL OF LIVER FIBROSIS VIA INHIBITION OF COLLAGEN CROSS-LINKING AND FIBROTIC MATRIX STABILIZATION

被引：0
|
作者：
Ikenaga, N. [1 ]
Yoshida, S. [1 ]
Liu, S. B. [1 ]
Chung, J. [1 ]
Sverdlov, D. [1 ]
Marshall, D. [2 ]
Smith, V. [2 ]
Kovalenko, M. [2 ]
Karnik, S. [2 ]
Afdhal, N. [1 ]
Popov, Y. [1 ]
机构：
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
[2] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60598-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
596
引用
收藏
页码：S243 / S244
页数：2
相关论文
共 46 条
  • [31] EFFECTS OF PROSTAGLANDIN E2 ON LYSYL OXIDASE-MEDIATED COLLAGEN CROSS-LINKING IN HUMAN AMNION FIBROBLASTS
    Liu, Chao
    Wang, Wangsheng
    Sun, Gang
    PLACENTA, 2014, 35 (09) : A44 - A45
  • [32] Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma
    Kurozumi, Akira
    Kato, Mayuko
    Goto, Yusuke
    Matsushita, Ryosuke
    Nishikawa, Rika
    Okato, Atsushi
    Fukumoto, Ichiro
    Ichikawa, Tomohiko
    Seki, Naohiko
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (05) : 1837 - 1846
  • [33] Lysyl oxidase-like-2 inhibition decreases cardiac fibrosis and improves diastolic dysfunction in experimental and clinical heart failure with preserved ejection fraction
    Savvatis, K.
    Yang, J.
    Kasner, M.
    Van Linthout, S.
    Fan, P.
    Diez, J.
    Yao, L.
    Chang, C. P.
    Tschoepe, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 141 - 141
  • [34] Lysyl oxidase-like-2 inhibition decreases cardiac fibrosis and improves diastolic dysfunction in experimental and clinical heart failure with preserved ejection fraction
    Savvatis, K.
    Yang, J.
    Kasner, M.
    Van Linthout, S.
    Fan, P.
    Yao, L.
    Chang, C. P.
    Tschoepe, C. P.
    EUROPEAN HEART JOURNAL, 2015, 36 : 365 - 365
  • [35] DIRECT REGULATION OF COLLAGEN CROSS-LINKING ENZYMES (LOXL2 AND PLOD2) BY TUMOR-SUPPRESSIVE MICRORNA-26A/B IN RENAL CELL CARCINOMA
    Kurozumi, Akira
    Kato, Mayuko
    Goto, Yusuke
    Okato, Atsushi
    Matsushita, Ryosuke
    Enokida, Hideki
    Nakagawa, Masayuki
    Ichikawa, Tomohiko
    Seki, Naohiko
    JOURNAL OF UROLOGY, 2016, 195 (04): : E1100 - E1100
  • [36] SIMTUZUMAB, AN ANTIFIBROTIC MONOCLONAL ANTIBODY AGAINST LYSYL OXIDASE-LIKE 2 (LOXL2) ENZYME, APPEARS SAFE AND WELL TOLERATED IN PATIENTS WITH LIVER DISEASE OF DIVERSE ETIOLOGY
    Talal, A. H.
    Feron-Rigodon, M.
    Madere, J.
    Subramanian, G. M.
    Bornstein, J. D.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S532 - S532
  • [37] Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma
    Im-kyung Kim
    Yun Sun Lee
    Hyung Sun Kim
    Seung Myung Dong
    Joon Seong Park
    Dong Sup Yoon
    Scientific Reports, 9
  • [38] Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma
    Kim, Im-Kyung
    Lee, Yun Sun
    Kim, Hyung Sun
    Dong, Seung Myung
    Park, Joon Seong
    Yoon, Dong Sup
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [39] Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes collagen cross-linking and ECM stiffening to induce liver fibrosis
    Yue, Wenhui
    Zhang, Hang
    Gao, Yue
    Ding, Jingru
    Xue, Renmin
    Dong, Chengbin
    Liu, Fuquan
    Yang, Lin
    Yang, Le
    Li, Liying
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2024, 1870 (05):
  • [40] Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease
    Dongiovanni, Paola
    Meroni, Marica
    Baselli, Guido Alessandro
    Bassani, Giulia Alessandra
    Rametta, Raffaela
    Pietrelli, Alessandro
    Maggioni, Marco
    Facciotti, Federica
    Trunzo, Valentina
    Badiali, Sara
    Fargion, Silvia
    Gatti, Stefano
    Valenti, Luca
    CLINICAL SCIENCE, 2017, 131 (12) : 1301 - 1315
12345